Clinical Feasibility Study to Evaluate the Safety & Performance of

Status Recruiting

Clinical Trial Summary

This is a non-randomized, multi-center, open-label clinical trial evaluating clinical feasibility treatments with the Profound Matrix system.

Clinical Trial Description

The Profound Matrix system is a multipurpose (3-in-1) radiofrequency (RF) platform. The clinical study is to evaluate the safety and performance of the Profound Matrix system with Sublime applicator, RF applicator and Matrix Pro applicator for aesthetic treatments including its cleared indications of wrinkles, acne scars, striae, and electrocoagulation and hemostasis. The Sublime and Sublative RF applicators are equivalent to those on the European conformity (CE) marked eLos, eTwo, eMatrix device family. The Matrix Pro applicator utilizes micro-needling technology and is new feature of the Profound Matrix system. The Profound Matrix system, including the Matrix Pro applicator are currently cleared for use in the US under FDA 510k K211217. This study aims to evaluate additional indications for treatment through the electrocoagulation and hemostasis mechanism of action for dermal remodeling and improvement in skin conditions to provide study subjects with a safe and effective alternative treatment that can be performed with minimal risks and decreased downtime. Eligible subjects would be healthy adult volunteers between 18 to 75 years of age seeking clinical treatment for indications as listed above. The research is sponsored by Candela Corporation and planned to be conducted at up to 20 sites globally. From the first subject enrollment to the last subject follow-up, the expected total duration is up to 5 years across all sites. The participants will undergo informed consent, screening and enrollment, treatments for the indication to be treated, and follow-up visits at no cost. The data from this research will assist Candela in optimizing treatment parameters, treatment guidelines, providing input to clinical education and marketing material, and support the research and development of micro-needling technology alongside energy-based devices. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06157567
Study type	Interventional
Source	Candela Corporation
Contact	Maya Duffy
Phone	508-948-8185
Email	maya.duffy@candelamedical.com
Status	Recruiting
Phase	N/A
Start date	May 24, 2022
Completion date	May 24, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05098912` - Comparing Polydioxanone Thread Embedding Acupuncture and Manual Acupuncture for Nasolabial Fold Reduction	N/A
Completed	`NCT05271136` - A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum	N/A
Completed	`NCT05096247` - Post Market Study To Collect Efficacy Data For The Treatment Of Wrinkles With A Radiofrequency Device	N/A
Completed	`NCT05097157` - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions	N/A
Completed	`NCT04128046` - The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation	N/A
Active, not recruiting	`NCT04727099` - Clinical Evaluation to Demonstrate the Safety and Performance of the Candela PicoWay System™	N/A
Active, not recruiting	`NCT06140628` - A 28-day Clinical Study on Facial Skin Rejuvenation	N/A
Not yet recruiting	`NCT05524779` - BTL-785F Device for Non-invasive Reduction of Wrinkles and Overall Facial Improvement	N/A
Completed	`NCT05514782` - A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum	N/A
Completed	`NCT06123572` - A Clinical Study to Assess the Safety and Effectiveness of Anti-Ageing and Skin Brightening Gel	N/A
Completed	`NCT04911374` - An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream	N/A
Recruiting	`NCT04989361` - Soluble Hyaluronic Acid Microneedle VS. Non-ablative Fractional Laser on Infraorbital Wrinkles.	N/A
Recruiting	`NCT04540900` - A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions	Phase 1
Recruiting	`NCT06074276` - The Effects of Almond on Facial Skin Collagen and Wrinkles	N/A
Recruiting	`NCT06202274` - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology	N/A
Completed	`NCT06366503` - Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation	N/A
Active, not recruiting	`NCT06219278` - A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles	N/A
Active, not recruiting	`NCT06192550` - Functional Usability and Feasibility Testing of the Profound Matrix™ System	N/A
Completed	`NCT04650620` - Study to Evaluate the Performance and Safety of the Medical Device Plenhyage®	N/A
Completed	`NCT03729700` - The Effect of Almonds on Facial Aesthetics and Modulation of the Microbiome and Lipidome	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms